Pharmacy & PharmacologyPharmacy & PharmacologyФармация и фармакология2307-92662413-2241Eco-Vector35257910.19163/2307-9266-2022-10-6-549-561ORIGINAL ARTICLESОРИГИНАЛЬНЫЕ СТАТЬИResearch ArticleDF-5 compound delays development of diabetic nephropathy in ratsСоединение ДФ-5 замедляет развитие диабетической нефропатии у крысhttps://orcid.org/0000-0002-7185-4826SpasovAlexander A.СпасовАлександр Алексеевич
Russian Federation

Doctor of Sciences (Medicine), Academician of RAS, Head of the Pharmacology and Bioinformatics Department, Volgograd State Medical University; Head of the Laboratory of Experimental Pharmacology, Volgograd Medical Research Center

доктор медицинских наук, академик РАН, заведующий кафедрой фармакологии и биоинформатики, ФГБОУ ВО ВолгГМУ Минздрава России; заведующий лабораторией экспериментальной фармакологии ГБУ ВМНЦ

aspasov@mail.ruhttps://orcid.org/0000-0003-2485-2139ZhukovskayaOlga N.ЖуковскаяОльга Николаевна
Russian Federation

Candidate of Sciences (Chemistry), Senior researcher of the Organic Synthesis Laboratory

кандидат химических наук, старший научный сотрудник лаборатории органического синтеза

zhukowskaia.ol@yandex.ruRashchenkoAndrey I.РащенкоАндрей Игоревич
Russian Federation

Candidate of Sciences (Pharmacy), Senior researcher of the Metabotropic Drugs Laboratory

кандидат фармацевтических наук, старший научный сотрудник лаборатории метаботропных лекарственных средств НЦИЛС

a.rashencko@yandex.ruhttps://orcid.org/0000-0003-0957-7087BrigadirovaAnasthasia A.БригадироваАнастасия Андреевна
Russian Federation

Candidate of Sciences (Medicine), Associate Professor, Pharmacology and Bioinformatics Department, Volgograd State Medical University; Volgograd Medical Research Center

кандидат медицинских наук, доцент кафедры фармакологии и биоинформатики ФГБОУ ВО ВолгГМУ Минздрава России; младший научный сотрудник лаборатории экспериментальной фармакологии ГБУ ВМНЦ

a.brigadirova@gmail.comhttps://orcid.org/0000-0002-0162-0653LitvinovRoman A.ЛитвиновРоман Александрович
Russian Federation

Candidate of Sciences (Medicine), Senior researcher of the Metabotropic drugs Laboratory, Volgograd State Medical University; Researcher of the Laboratory of Experimental Pharmacology, Volgograd Medical Research Center

кандидат медицинских наук, старший научный сотрудник лаборатории метаботропных лекарственных средств НЦИЛС, ФГБОУ ВО ВолгГМУ Минздрава России; научный сотрудник лаборатории экспериментальной фармакологии ГБУ ВМНЦ

litvinov.volggmu@mail.ruhttps://orcid.org/0000-0002-0670-1444GurovaNatalia A.ГуроваНаталия Алексеевна
Russian Federation

Doctor of Sciences (Medicine), Professor of the Pharmacology and Bioinformatics Department

доктор медицинских наук, профессор кафедры фармакологии и биоинформатики

gurova.vlgmed@mail.ruhttps://orcid.org/0000-0001-5351-6105SmirnovAlexey V.СмирновАлексей Владимирович
Russian Federation

Doctor of Sciences (Medicine), Head of the Pathological Anatomy Department, Volgograd State Medical University

доктор медицинских наук, заведующий кафедрой патологической анатомии ФГБОУ ВО ВолгГМУ Минздрава России

alexey-smirnov@rambler.ruhttps://orcid.org/0000-0002-4035-4108Pan’shinNicolay G.ПаньшинНиколай Геннадьевич
Russian Federation

Candidate of Sciences (Medicine), Associate Professor, Pathological Anatomy Department

кандидат медицинских наук, доцент кафедры патологической анатомии

panshin.nickolay@gmail.comAbbasHaider S.A.АббасХайдер Сабри Аббас
Russian Federation

Master’s student of the Organic Synthesis Laboratory

магистрант лаборатории органического синтеза

vip.haider89@gmail.ruhttps://orcid.org/0000-0002-9182-6101MorkovnikAnatoliy S.МорковникАнатолий Савельевич
Russian Federation

Doctor of Sciences (Chemistry), Chief Researcher, Organic Synthesis Laboratory

доктор химических наук, главный научный сотрудник лаборатории органического синтеза

asmork@mail.ruVolgograd State Medical UniversityФедеральное государственное бюджетное образовательное учреждение высшего образования «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииVolgograd Medical Research CenterГосударственное бюджетное учреждение «Волгоградский медицинский научный центр»Institute of Physical and Organic Chemistry, Southern Federal UniversityНаучно-исследовательский институт физической и органической химии федеральное государственное автономное образовательное учреждение высшего профессионального образования «Южный федеральный университет»Volgograd Medical Research CenterГосударственное бюджетное учреждение «Волгоградский медицинский научный центр»Volgograd State Medical UniversityФедеральное государственное бюджетное образовательное учреждение высшего образования «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииInstitute of Physical and Organic Chemistry, Southern Federal UniversityНаучно-исследовательский институт физической и органической химии федеральное государственное автономное образовательное учреждение высшего профессионального образования «Южный федеральный университет»021220221065495612704202327042023Copyright ©; 2022, Spasov A.A., Zhukovskaya O.N., Rashchenko A.I., Brigadirova A.A., Litvinov R.A., Gurova N.A., Smirnov A.V., Pan’shin N.G., Abbas H.S., Morkovnik A.S.Copyright ©; 2022, Спасов А.А., Жуковская О.Н., Ращенко А.И., Бригадирова А.А., Литвинов Р.А., Гурова Н.А., Смирнов А.В., Паньшин Н.Г., Аббас Х.С., Морковник А.С.Copyright ©; 2022, Spasov A., Zhukovskaya O., Rashchenko A., Brigadirova A., Litvinov R., Gurova N., Smirnov A., Pan’shin N., Abbas H., Morkovnik A.2022Spasov A.A., Zhukovskaya O.N., Rashchenko A.I., Brigadirova A.A., Litvinov R.A., Gurova N.A., Smirnov A.V., Pan’shin N.G., Abbas H.S., Morkovnik A.S.Спасов А.А., Жуковская О.Н., Ращенко А.И., Бригадирова А.А., Литвинов Р.А., Гурова Н.А., Смирнов А.В., Паньшин Н.Г., Аббас Х.С., Морковник А.С.Spasov A., Zhukovskaya O., Rashchenko A., Brigadirova A., Litvinov R., Gurova N., Smirnov A., Pan’shin N., Abbas H., Morkovnik A.https://creativecommons.org/licenses/by/4.0https://journals.eco-vector.com/2307-9266/article/view/352579

Advanced glycation end-products play an important role in the development of diabetic complications, so slowing down of glycated proteins’ cross-links formation have been suggested as a potential therapeutic option for the treatment of vascular diabetic complications and preventing their progression.

The aim of the work was to assess the influence of novel anticrosslinking agent DF-5 on the renal advanced glycation end-products and collagen contents, body weight, blood glucose and glycated hemoglobin levels and the development of early renal disease in streptozotocin-induced diabetic rats.

Materials and methods. 40 male Sprague-Dawley rats were used in the study. Two months after inducing diabetes, the study substance was administered intragastrically once a day for 28 days (12.5 mg/kg). Measurements included the assessment of blood glucose and HbA1c levels, the evaluation of the renal function, and the results of histology and immunohistochemical staining of kidneys.

Results. A repeated intragastric administration of DF-5 for 30 days significantly reduced the level of HbA1c in the blood, but did not affect the level of fasting blood glucose. DF-5 compound significantly reduced proteinuria and prevented kidney damage in experimental animals by limiting damage of the glomeruli and tubules. It was found that DF-5 inhibits the progression of an early renal dysfunction in rats with streptozotocin-induced diabetic nephropathy. This was associated with a decreased accumulation of advanced glycation end-products in the kidney, accompanied by the improvement of both renal morphology and function.

Conclusion. The results obtained provide investigators with additional therapeutic options for the treatment of diabetic nephropathy and possibly other complications of diabetes.

Конечные продукты гликирования играют важную роль в развитии осложнений сахарного диабета. По этой причине замедление образования поперечных сшивок гликированных белков, как предполагается, является потенциальным терапевтическим подходом к лечению и профилактике осложнений заболевания, связанных с поражением сосудов.

Цель. Оценка способности нового антисшивающего соединения ДФ-5 влиять на количество конечных продуктов гликирования и коллагена в почках, на массу тела, уровни глюкозы и гликированного гемоглобина, а также на развитие ранних проявлений поражения почек у крыс со стрептозотоциновым сахарным диабетом.

Материалы и методы. Работа проведена на 40 самцах крыс Sprague-Dawley. Через 2 месяца после индукции диабета исследуемое вещество вводили внутрижелудочно (12,5 мг/кг) 1 р/сут в течение 28 дней с помощью зонда. Определяли уровень глюкозы и гликированного гемоглобина в крови, оценивали функцию почек, а также проводили гистологическое и иммуногистохимическое исследования тканей почек.

Результаты. Регулярное внутрижелудочное введение ДФ-5 в течение 30 сут статистически значимо снижало уровень HbA1c в крови, но не влияло на уровень глюкозы в крови натощак. Соединение ДФ-5 существенно уменьшало протеинурию и предотвращало повреждение почек у экспериментальных животных за счет ограничения повреждений клубочков и канальцев. Было установлено, что соединение ДФ-5 замедляет повреждение почек на ранней стадии диабетической нефропатии, что сопровождается снижением количества конечных продуктов гликирования в ткани почек, улучшением их морфологической картины и функции.

Заключение. Полученные результаты открывают возможность для разработки дополнительного терапевтического подхода к лечению диабетической нефропатии и, возможно, других осложнений сахарного диабета.

advanced glycation endproductscross-linksALT-711 (alagebrium)diabetes mellitusdiabetic kidney disease (nephropathy)streptozotocin-induced diabetesконечные продукты гликированияпоперечные сшивкиALT-711 (алагебриум)сахарный диабетдиабетическая болезнь почек (нефропатия)стрептозотоцин-индуцированный диабетThe chemical part of this work was carried out in the Institute of Organic and Physical Chemistry, Southern Federal University with a financial support by the Ministry of Science and Higher Education of the Russian Federation in the framework of the state task, grant FENW-2020-0031 (0852-2020-0031). The biological part of this work was financially supported by the Russian Science Foundation (Project 14-25-00139)Химическая часть исследования выполнена в Институте органической и физической химии ФГАОУ ВПО «Южный федеральный университет» при финансовой поддержке Министерства науки и высшего образования Российской Федерации в рамках государственного задания, грант ФЕНВ-2020-0031 (0852-2020-0031). Биологическая часть исследования проведена при финансовой поддержке Российского научного фонда (проект 14-25-00139)Silva JAD, Souza ECF, Echazú Böschemeier AG, Costa CCMD, Bezerra HS, Feitosa EELC. Diagnosis of diabetes mellitus and living with a chronic condition: participatory study. BMC Public Health. 2018 Jun 5;18(1):699. DOI:10.1186/s12889-018-5637-9Silva J.A.D., Souza E.C.F., Echazú Böschemeier A.G., Costa C.C.M.D., Bezerra H.S., Feitosa E.E.L.C. Diagnosis of diabetes mellitus and living with a chronic condition: participatory study // BMC Public Health. – 2018. – Vol. 18, No. 1. – Art. ID: 699. DOI:10.1186/s12889-018-5637-9Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014 Feb;18(1):1–14. DOI:10.4196/kjpp.2014.18.1.1Singh V.P., Bali A., Singh N., Jaggi A.S. Advanced Glycation End Products and Diabetic Complications // Korean J. Physiol. Pharmacol. – 2014. – Vol. 18, No. 1. – P. 1–14. DOI:10.4196/kjpp.2014.18.1.1Rhee SY, Kim YS. The Role of Advanced Glycation End Products in Diabetic Vascular Complications. Diabetes Metab J. 2018 Jun;42(3):188–95. DOI:10.4093/dmj.2017.0105Rhee S.Y., Kim Y.S. The Role of Advanced Glycation End Products in Diabetic Vascular Complications // Diabetes Metab. J. – 2018. – Vol. 42, No. 3. – P. 188–195. DOI:10.4093/dmj.2017.0105Chaudhuri J, Bains Y, Guha S, Kahn A, Hall D, Bose N, Gugliucci A, Kapahi P. The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality. Cell Metab. 2018 Sep 4;28(3):337–52. DOI:10.1016/j.cmet.2018.08.014Chaudhuri J., Bains Y., Guha S., Kahn A., Hall D., Bose N., et al. The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality // Cell Metab. – 2018. – Vol .28, No. 3. – P. 337–352. DOI:10.1016/j.cmet.2018.08.014Bodiga VL, Eda SR, Bodiga S. Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart Fail Rev. 2014 Jan;19(1):49–63. DOI:10.1007/s10741-013-9374-yBodiga V.L., Eda S.R., Bodiga S. Advanced glycation end products: role in pathology of diabetic cardiomyopathy // Heart Fail Rev. – 2014. – Vol. 19, No. 1. – P. 49–63. DOI:10.1007/s10741-013-9374-yBhat S, Mary S, Giri AP, Kulkarni MJ. Advanced Glycation End Products (AGEs) in Diabetic Complications. In: Kartha CC, Ramachandran S, Pillai RM, editors. Mechanisms of Vascular Defects in Diabetes Mellitus, Cham: Springer International Publishing; 2017, p. 423–49. DOI:10.1007/978-3-319-60324-7_19Bhat S., Mary S., Giri A.P., Kulkarni M.J. Advanced Glycation End Products (AGEs) in Diabetic Complications / Mechanisms of Vascular Defects in Diabetes Mellitus. Advances in Biochemistry in Health and Disease // Edited by Kartha C.C., Ramachandran S., Pillai R.M. Cham: Springer International Publishing, 2017. – P. 423–449. DOI:10.1007/978-3-319-60324-7_19Rabbani N, Thornalley PJ. Advanced glycation end products in the pathogenesis of chronic kidney disease. Kidney Int. 2018 Apr;93(4):803–13. DOI:10.1016/j.kint.2017.11.034Rabbani N., Thornalley P.J. Advanced glycation end products in the pathogenesis of chronic kidney disease // Kidney Int. – 2018. – Vol. 93, No. 4 – P. 803–813. DOI:10.1016/j.kint.2017.11.034Nabi R, Alvi SS, Saeed M, Ahmad S, Khan MS. Glycation and HMG-CoA Reductase Inhibitors: Implication in Diabetes and Associated Complications. Curr Diabetes Rev. 2019;15(3):213–23. DOI:10.2174/1573399814666180924113442Nabi R., Alvi S.S., Saeed M., Ahmad S., Khan M.S. Glycation and HMG-CoA Reductase Inhibitors: Implication in Diabetes and Associated Complications // Curr. Diabetes Rev. – 2019. – Vol. 15, No. 3. – P. 213–223. DOI:10.2174/1573399814666180924113442Nabi R, Alvi SS, Khan RH, Ahmad S, Ahmad S, Khan MS. Antiglycation study of HMG-R inhibitors and tocotrienol against glycated BSA and LDL: A comparative study. Int J Biol Macromol. 2018 Sep;116:983–92. DOI:10.1016/j.ijbiomac.2018.05.115Nabi R., Alvi S.S., Khan R.H., Ahmad S., Ahmad S., Khan M.S. Antiglycation study of HMG-R inhibitors and tocotrienol against glycated BSA and LDL: A comparative study // Int. J. Biol. Macromol. – 2018. – Vol. 116. – P. 983–992. DOI:10.1016/j.ijbiomac.2018.05.115Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys. 2003 Nov 1;419(1):63–79. DOI:10.1016/j.abb.2003.08.009Rahbar S., Figarola J.L. Novel inhibitors of advanced glycation endproducts // Arch. Biochem. Biophys. – 2003. – Vol. 419, No. 1. – P. 63–79. DOI:10.1016/j.abb.2003.08.009Akhter F, Khan MS, Ahmad S. Acquired immunogenicity of calf thymus DNA and LDL modified by D-ribose: a comparative study. Int J Biol Macromol. 2015 Jan;72:1222-7. DOI:10.1016/j.ijbiomac.2014.10.034Akhter F., Khan M.S., Ahmad S. Acquired immunogenicity of calf thymus DNA and LDL modified by D-ribose: a comparative study // Int. J. Biol. Macromol. – 2015. – Vol. 72. – P. 1222–1227. DOI:10.1016/j.ijbiomac.2014.10.034Jabir NR, Ahmad S, Tabrez S. An insight on the association of glycation with hepatocellular carcinoma. Semin Cancer Biol. 2018 Apr;49:56–63. DOI:10.1016/j.semcancer.2017.06.005Jabir N.R., Ahmad S., Tabrez S. An insight on the association of glycation with hepatocellular carcinoma // Semin. Cancer. Biol. – 2018. – Vol. 49. – P. 56–63. DOI:10.1016/j.semcancer.2017.06.005Brings S, Fleming T, Freichel M, Muckenthaler MU, Herzig S, Nawroth PP. Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention. Int J Mol Sci. 2017 May 5;18(5):984. DOI:10.3390/ijms18050984Brings S., Fleming T., Freichel M., Muckenthaler M.U., Herzig S., Nawroth P.P. Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention // Int. J. Mol. Sci. – 2017. – Vol. 18, No. 5. – Art. ID: 984. DOI:10.3390/ijms18050984Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys. 2003 Nov 1;419(1):89–96. DOI:10.1016/j.abb.2003.08.016Vasan S., Foiles P., Founds H. Therapeutic potential of breakers of advanced glycation end product–protein crosslinks // Arch. Biochem. Biophys. – 2003. – Vol. 419, No. 1. – P. 89–96. DOI:10.1016/j.abb.2003.08.016Zuehlke CW. Methods of Organic Elemental Microanalysis. J Am Chem Soc. 1963;85(16):2536. DOI:10.1021/ja00899a055Zuehlke C.W. Methods of Organic Elemental Microanalysis // J. Am. Chem. Soc. – 1963. – Vol. 85, No. 16. – Art. ID: 2536. DOI:10.1021/ja00899a055Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature. 1996 Jul 18;382(6588):275–8. DOI:10.1038/382275a0Vasan S., Zhang X., Zhang X., Kapurniotu A., Bernhagen J., Teichberg S., Basgen J., Wagle D., Shih D., Terlecky I., Bucala R., Cerami A., Egan J., Ulrich P. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo // Nature. – 1996. – Vol. 382, No. 6588. – P. 275–278. DOI:10.1038/382275a0Zhukovskaya ON, Anisimova VA, Morkovnik AS, Petrov VI, Spasov AA, Rashchenko AI, Brigadirova AA, Abbas HSA. 9-Benzyl-2-biphenylimidazo[1,2-a]benzimidazole and pharmaceutically acceptable salts thereof that express properties of destroyers of transversal cross-links of glycosylated proteins. RU 2627769 C1, 2017.Жуковская О.Н., Анисимова В.А., Морковник А.С., Петров В.И., Спасов А.А., Ращенко А.И., Бригадирова А.А., Аббас Х.С.А. 9-бензил-2-бифенилимидазо[1,2-а]бензимидазол и его фармацевтически приемлемые соли, проявляющие свойства разрушителей поперечных сшивок гликированных белков. RU 2627769 C1, 2017.Zhang B, He K, Chen W, Cheng X, Cui H, Zhong W, Li S, Wang L. Alagebrium (ALT-711) improves the anti-hypertensive efficacy of nifedipine in diabetic-hypertensive rats. Hypertens Res. 2014 Oct;37(10):901–7. DOI: 10.1038/hr.2014.98Zhang B., He K., Chen W., Cheng X., Cui H., Zhong W., Li S., Wang L. Alagebrium (ALT-711) improves the anti-hypertensive efficacy of nifedipine in diabetic-hypertensive rats // Hypertens. Res. – 2014. – Vol. 37, No. 10. – P. 901–907. DOI:10.1038/hr.2014.98Cheng G, Wang LL, Qu WS, Long L, Cui H, Liu HY, Cao YL, Li S. C16, a novel advanced glycation endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats. Acta Pharmacol Sin. 2005 Dec; 26(12):1460–6. DOI:10.1111/j.1745-7254.2005.00240.xCheng G., Wang L.L., Qu W.S., Long L., Cui H., Liu H.Y., Cao Y.L., Li S. C16, a novel advanced glycation endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats // Acta Pharmacol. Sin. – 2005. – Vol. 26, No. 12. – P. 1460–1466. DOI:10.1111/j.1745-7254.2005.00240.xCheng G, Wang LL, Long L, Liu HY, Cui H, Qu WS, Li S. Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats. Br J Pharmacol. 2007 Dec;152(8):1196–206. DOI:10.1038/sj.bjp.0707533Cheng G., Wang L.L., Long L., Liu H.Y., Cui H., Qu W.S., Li S. Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats // Br. J. Pharmacol. – 2007. – Vol. 152, No. 8. – P. 1196–1206. DOI:10.1038/sj.bjp.0707533Spasov AA, Zhukovskaya ON, Brigadirova AA, Abbas HSA, Anisimova VA, Sysoeva VA, Rashchenko AI, Litvinov RA, Mayka OYu, Babkov DA, Morkovnik AS. Synthesis and pharmacological activity of 2-(biphenyl-4-yl)imidazo[1,2-a]benzimidazoles. Russ Chem Bull. 2017;66:1905–1912. DOI: 10.1007/s11172-017-1965-7Spasov A.A., Zhukovskaya O.N., Brigadirova A.A., Abbas H.S.A., Anisimova V.A., Sysoeva V.A., Rashchenko A.I., Litvinov R.A., Mayka O.Yu., Babkov D.A., Morkovnik A.S. Synthesis and pharmacological activity of 2-(biphenyl-4-yl)imidazo[1,2-a]benzimidazoles // Russ. Chem. Bull. – 2017. – Vol. 66. – P. 1905–1912. DOI:10.1007/s11172-017-1965-7Cho SJ, Roman G, Yeboah F, Konishi Y. The road to advanced glycation end products: a mechanistic perspective. Curr Med Chem. 2007;14(15):1653–71. DOI:10.2174/092986707780830989Cho S.J., Roman G., Yeboah F., Konishi Y. The Road to Advanced Glycation End Products: A Mechanistic Perspective // Curr. Med. Chem. – 2007. – Vol. 14, No. 15. – P. 1653–1671. DOI:10.2174/092986707780830989Tang SCW, Yiu WH. Innate immunity in diabetic kidney disease. Nat Rev Nephrol. 2020 Apr;16(4):206–22. DOI:10.1038/s41581-019-0234-4Tang S.C.W., Yiu W.H. Innate immunity in diabetic kidney disease // Nat. Rev. Nephrol. 2020- Vol. 16. – P. 206–222. DOI:10.1038/s41581-019-0234-4Yao D, Wang S, Wang M, Lu W. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1-receptor for advanced glycation end products-nuclear factor-κB signaling pathway. Mol Med Rep. 2018 Oct;18(4):3625–30. DOI:10.3892/mmr.2018.9393Yao D., Wang S., Wang M., Lu W. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1receptor for advanced glycation end productsnuclear factorκB signaling pathway // Mol. Med. Rep. – 2018. – Vol. 18, No. 4. – P. 3625–3630. DOI:10.3892/mmr.2018.9393.Kolset SO, Reinholt FP, Jenssen T. Diabetic nephropathy and extracellular matrix. J Histochem Cytochem. 2012 Dec;60(12):976–86. DOI:10.1369/0022155412465073Kolset S.O., Reinholt F.P., Jenssen T. Diabetic Nephropathy and Extracellular Matrix // J. Histochem. Cytochem. – 2012. – Vol. 60, No. 12. – P. 976–986. DOI: 10.1369/0022155412465073Dalla Vestra M, Saller A, Mauer M, Fioretto P. Role of mesangial expansion in the pathogenesis of diabetic nephropathy. J Nephrol. 2001 Nov-Dec;14 Suppl 4:S51-7.Dalla Vestra M., Saller A., Mauer M., Fioretto P. Role of mesangial expansion in the pathogenesis of diabetic nephropathy // J. Nephrol. – 2001. – Vol. 14, Suppl 4. – P. 51–57.Amorim RG, Guedes GDS, Vasconcelos SML, Santos JCF. Kidney Disease in Diabetes Mellitus: Cross-Linking between Hyperglycemia, Redox Imbalance and Inflammation. Arq Bras Cardiol. 2019 Jun 6;112(5):577–87. DOI:10.5935/abc.20190077. Erratum in: Arq Bras Cardiol. 2019 Aug 08;113(1):182.Amorim R.G., Guedes G. da S., Vasconcelos S.M. de L., Santos J.C. de F. Kidney Disease in Diabetes Mellitus: Cross-Linking between Hyperglycemia, Redox Imbalance and Inflammation // Arq. Bras. Cardiol. – 2019. – Vol. 112, No. 5. – P. 577-587. DOI: 10.5935/abc.20190077. Erratum in: Arq. Bras. Cardiol. – 2019. – Vol. 113, No. 1. – Art. ID: 182.Vasan S, Foiles PG, Founds HW. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin Investig Drugs. 2001 Nov;10(11):1977–87. DOI:10.1517/13543784.10.11.1977Vasan S., Foiles P.G., Founds H.W. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links // Expert Opin. Investig. Drugs. – 2001. – Vol. 10, No. 11. – P. 1977–1987. DOI:10.1517/13543784.10.11.1977Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 2003 Sep;17(12):1762–4. DOI:10.1096/fj.02-1102fjeForbes J.M., Thallas V., Thomas M.C., Founds H.W., Burns W.C., Jerums G., Cooper ME. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes // FASEB J. – 2003. – Vol. 17, No. 12. – P. 1762–1764. DOI:10.1096/fj.02-1102fjeKim YS, Kim J, Kim CS, Sohn EJ, Lee YM, Jeong IH, Kim H, Jang DS, Kim JS. KIOM-79, an Inhibitor of AGEs-Protein Cross-linking, Prevents Progression of Nephropathy in Zucker Diabetic Fatty Rats. Evid Based Complement Alternat Med. 2011;2011:761859. DOI:10.1093/ecam/nep078Kim Y.S., Kim J., Kim C.S., Sohn E.J., Lee Y.M., Jeong I.H., Kim H., Jang D.S., Kim J.S. KIOM-79, an Inhibitor of AGEs–Protein Cross-linking, Prevents Progression of Nephropathy in Zucker Diabetic Fatty Rats // Evid. Based Complement. Alternat. Med. – 2011. – Vol. 2011. – P. 1–10. DOI:10.1093/ecam/nep078Jung E, Park SB, Jung WK, Kim HR, Kim J. Antiglycation Activity of Aucubin In Vitro and in Exogenous Methylglyoxal Injected Rats. Molecules. 2019 Oct 10;24(20):3653. DOI:10.3390/molecules24203653Jung E., Park S.B., Jung W.K., Kim H.R., Kim J. Antiglycation Activity of Aucubin In Vitro and in Exogenous Methylglyoxal Injected Rats // Molecules. – 2019. – Vol. 24, No. 20. – Art. ID: 3653. DOI:10.3390/molecules24203653Kim J, Kim CS, Kim YS, Lee IS, Kim JS. Jakyakgamcho-tang and Its Major Component, Paeonia Lactiflora, Exhibit Potent Anti-glycation Properties. J Exerc Nutrition Biochem. 2016 Dec 31;20(4):60–4. DOI:10.20463/jenb.2016.0049Kim J., Kim C.S., Kim Y.S., Lee I.S., Kim J.S. Jakyakgamcho-tang and Its Major Component, Paeonia Lactiflora, Exhibit Potent Anti-glycation Properties // J. Exerc. Nutrition Biochem. – 2016. – Vol. 20, No. 4. – P. 60–64. DOI:10.20463/jenb.2016.0049Kim CS, Jo K, Pyo MK, Kim JS, Kim J. Pectin lyase-modified red ginseng extract exhibits potent anti-glycation effects in vitro and in vivo. J Exerc Nutrition Biochem. 2017 Jun 30;21(2):56–62. DOI:10.20463/jenb.2017.0011Kim C.S., Jo K., Pyo M.K., Kim J.S., Kim J. Pectin lyase-modified red ginseng extract exhibits potent anti-glycation effects in vitro and in vivo // J. Exerc. Nutrition Biochem. – 2017. – Vol. 21, No. 2. – P. 56–62. DOI:10.20463/jenb.2017.0011Coughlan MT, Forbes JM, Cooper ME. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney International. 2007;72(Suppl 106): 54–60. DOI:doi.org/10.1038/sj.ki.5002387Coughlan M.T., Forbes J.M., Cooper M.E. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes // Kidney International. – 2007. – Vol. 72, Suppl. 106. – P. 54–60. DOI:10.1038/sj.ki.5002387Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, Haller H, Cooper ME, Forbes JM. Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy by the Advanced Glycation End Product Cross-Link Breaker ALT-711 via a Protein Kinase C- -Dependent Pathway. Diabetes. 2004;53:2921–30. DOI:10.2337/diabetes.53.11.2921Thallas-Bonke V., Lindschau C., Rizkalla B., Bach L.A., Boner G., Meier M., Haller H., Cooper M.E., Forbes J.M. Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy by the Advanced Glycation End Product Cross-Link Breaker ALT-711 via a Protein Kinase C- -Dependent Pathway // Diabetes. – 2004. – Vol. 53. – P. 2921–2930. DOI:10.2337/diabetes.53.11.2921Yang S, Litchfield JE, Baynes JW. AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch Biochem Biophys. 2003 Apr 1;412(1):42–6. DOI:10.1016/s0003-9861(03)00015-8Yang S., Litchfield J.E., Baynes J.W. AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats // Arch. Biochem. Biophys. – 2003. – Vol. 412, No. 1. – P. 42–46. DOI:10.1016/S0003-9861(03)00015-8Nasiri R, Field MJ, Zahedi M, Moosavi-Movahedi AA. Cross-linking mechanisms of arginine and lysine with α,β-dicarbonyl compounds in aqueous solution. J Phys Chem A. 2011 Nov 24;115(46):13542–55. DOI:10.1021/jp205558dNasiri R., Field M.J., Zahedi M., Moosavi-Movahedi A.A. Cross-Linking Mechanisms of Arginine and Lysine with α,β-Dicarbonyl Compounds in Aqueous Solution // J. Phys. Chem. A. – 2011. – Vol. 115, No. 46. – P. 13542–13555. DOI:10.1021/jp205558dNasiri R, Field MJ, Zahedi M, Moosavi-Movahedi AA. Comparative DFT Study To Determine if α-Oxoaldehydes are Precursors for Pentosidine Formation. J Phys Chem A 2012;116(11):2986–96. DOI:10.1021/jp2104165Nasiri R., Field M.J., Zahedi M., Moosavi-Movahedi A.A. Comparative DFT Study To Determine if α-Oxoaldehydes are Precursors for Pentosidine Formation // J. Phys. Chem. A. – 2012. – Vol. 116, No. 11. – P. 2986–2996. DOI:10.1021/jp2104165Nobécourt E, Zeng J, Davies MJ, Brown BE, Yadav S, Barter PJ, Rye KA. Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I. Diabetologia. 2008 Jun;51(6):1008–17. DOI:10.1007/s00125-008-0986-zNobécourt E., Zeng J., Davies M.J., Brown B.E., Yadav S., Barter P.J., Rye K.A. Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I // Diabetologia. – 2008. – Vol. 51, No. 6. – P. 1008–1017. DOI:10.1007/s00125-008-0986-zKim T, Spiegel DA. The unique reactivity of N-phenacyl-derived thiazolium salts toward α-dicarbonyl compounds. Rejuvenation Res. 2013 Feb;16(1):43–50. DOI:10.1089/rej.2012.1370Kim T., Spiegel D.A. The Unique Reactivity of N-Phenacyl-Derived Thiazolium Salts Toward α-Dicarbonyl Compounds // Rejuvenation Res. – 2013. – Vol. 16, No. 1. – P. 43–50. DOI:10.1089/rej.2012.1370Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomark Insights. 2016 Jul 3;11: 95–104. DOI:10.4137/BMI.S38440Sherwani S.I., Khan H.A., Ekhzaimy A., Masood A., Sakharkar M.K. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients // Biomark Insights. – 2016. – Vol. 11. – P. 95–104. DOI:10.4137/BMI.S38440Nagai R, Murray DB, Metz TO, Baynes JW. Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes. 2012 Mar;61(3):549–59. DOI:10.2337/db11-1120Nagai R., Murray D.B., Metz T.O., Baynes J.W. Chelation: A Fundamental Mechanism of Action of AGE Inhibitors, AGE Breakers, and Other Inhibitors of Diabetes Complications // Diabetes. 2012. – Vol. 61, No. 3. – P. 549–559. DOI:10.2337/db11-1120Toprak C, Yigitaslan S. Alagebrium and Complications of Diabetes Mellitus. Eurasian J Med. 2019 Oct;51(3): 285–92. DOI:10.5152/eurasianjmed.2019.18434Toprak C., Yigitaslan S. Alagebrium and Complications of Diabetes Mellitus // Eurasian J. Med. – 2019. – Vol. 51, No. 3. – P. 285–292. DOI:10.5152/eurasianjmed.2019.18434